In our panel of cancer cells with EGFRvIII (U87MG), EGFR-mut NSCLCs exhibiting gefitinib (TKI)-sensitive (HCC827), partially resistant (PC9), and resistant (H1975), treatment with several specific and distinct mTOR inhibitors all led to significant inhibition in both basal- and EGF-stimulated level of TF expression. The gene discussed is TF; the disease is cancer.